Drug Profile

Interferon alpha hybrid - Alfacyte

Latest Information Update: 28 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Strathclyde
Developer Alfacyte; University of Edinburgh
Class Antiallergics; Antineoplastics; Interferons; Skin disorder therapies
Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Interleukin-22 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Autoimmune disorders; Food hypersensitivity

28 Jun 2021 No recent reports of development identified for research development in Cancer in United Kingdom (PO)
28 Sep 2020 No recent reports of development identified for research development in Psoriasis in United Kingdom (Topical)
28 Aug 2019 No recent reports of development identified for research development in Food-hypersensitivity in United Kingdom (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com